One To Watch

CytomX Therapeutics

A Nasdaq-listed clinical-stage biotechnology company developing conditionally activated biologics for cancer. CytomX Therapeutics focuses on masking potent therapies so they are activated selectively within the tumor microenvironment.

Company Overview

CytomX Therapeutics is an oncology-focused biopharmaceutical company developing a pipeline of biologic therapies designed to improve the therapeutic window of cancer treatments. Its core strategy is to engineer drugs that remain inactive in healthy tissue and become activated only within tumors.

The company’s approach is built on its proprietary Probody platform, which modifies antibodies and other biologics with masking peptides that are cleaved by proteases present in tumors. This conditional activation is intended to reduce systemic toxicity while maintaining efficacy.

CytomX operates as a clinical-stage developer with multiple internal and partnered programs across antibody-drug conjugates, cytokines and other biologic modalities.

Headquarters and Global Presence

CytomX Therapeutics is headquartered in South San Francisco, California, in the United States.

The company conducts clinical development globally and collaborates with pharmaceutical partners and research institutions to advance its oncology programs.

Founding and History

CytomX Therapeutics was founded in 2008 and became publicly listed on Nasdaq in 2015.

The company was established to develop conditionally activated biologics capable of improving the safety and efficacy of antibody-based therapies. Over time it has expanded its pipeline through internal development and partnerships with major pharmaceutical companies.

The company has undergone periodic strategic refocusing, including prioritizing wholly owned clinical programs and reallocating resources toward later-stage assets.

Therapy Areas and Focus

CytomX is focused exclusively on oncology.

Key areas of development include:

solid tumors, including colorectal cancer
tumor microenvironment-targeted therapies
combination immuno-oncology approaches

The company targets cancers where conventional biologics are limited by systemic toxicity or insufficient tumor selectivity.

Technology Platforms and Modalities

The company’s platform is centered on Probody therapeutics.

Key elements include:

conditionally activated (masked) biologics
antibody-drug conjugates (ADCs)
masked cytokines and immune modulators
protease-activated targeting within the tumor microenvironment

This approach allows potent biologics to remain inactive in circulation and become activated only in tumor tissue, improving selectivity and tolerability.

Key Pipeline and Programs

CX-2051

Modality: Probody antibody-drug conjugate (ADC) targeting EpCAM
Indication focus: advanced metastatic colorectal cancer
Status: clinical development with Phase 1 studies ongoing
Mechanism: tumor-activated ADC delivering cytotoxic payload selectively to cancer cells

CX-801

Modality: masked interferon alpha-2b cytokine therapy
Indication focus: solid tumors
Status: clinical development
Mechanism: conditional activation of cytokine activity within tumors to enhance immune response

Additional Probody programs

Modality: masked antibodies and biologics
Indication focus: multiple oncology targets
Status: preclinical and partnered development

The pipeline includes both wholly owned assets and collaboration programs with pharmaceutical partners.

Key Personnel

Sean McCarthy, Chief Executive Officer

Strategic Partnerships

Partnerships are central to CytomX’s development model.

Key collaborations include:

AbbVie, for development of Probody therapeutics in oncology
Amgen, Bristol Myers Squibb and Moderna in earlier or ongoing collaborations
additional pharmaceutical partners supporting clinical development and commercialization

These partnerships provide funding, validation and access to development infrastructure.

FAQ Section

The central strategic issue is whether conditionally activated biologics can demonstrate clear clinical advantages over conventional antibody and immunotherapy approaches. Validation of the Probody platform in late-stage trials will determine its long-term relevance.

Many biologic cancer therapies are limited by systemic toxicity. Masking these therapies and activating them only within tumors may allow higher effective dosing and improved safety profiles.

The Probody platform engineers biologics with peptide masks that are cleaved by tumor-associated proteases. This enables drugs to remain inactive in healthy tissue and become active only in the tumor microenvironment.

CX-2051 is the company’s lead wholly owned program and a key test of the Probody ADC approach. Its development in colorectal cancer represents the primary near-term value driver.

CytomX is focused exclusively on oncology, particularly solid tumors where targeted delivery and reduced toxicity are critical.

The company combines internal pipeline development with strategic partnerships. It prioritizes conditionally activated biologics across multiple modalities, including ADCs and cytokines.

Key issues include:

clinical efficacy and safety data from CX-2051 and other programs
validation of the Probody platform across multiple modalities
durability of partnerships with large pharmaceutical companies
financial sustainability and ability to advance programs into late-stage development

Want to Update your Company's Profile?